Managing the Screen Failure Rate in NASH Clinical Trials

Stetoscope Vlvbio

The Use of Cytokeratin 18 Assays as a Prescreening Tool

Read the blog post on how to use the Keratin 18 assays in NASH clinical trials!

Non‐alcoholic fatty liver disease (NAFLD) is a growing global epidemic and the most common cause of liver disease in all Western countries. NAFLD refers to a spectrum of conditions and it is defined as the excessive accumulation of fat in the liver not caused by heavy alcohol consumption.

Patients with non-alcoholic steatohepatitis (NASH), a more advanced form of NAFLD, are at an increased risk for liver-related mortality and cardiovascular disease. There are currently no approved drug therapies for NAFLD or NASH and many clinical trials are underway to address this unmet need for pharmacologic treatment options.

Read about the challenges faced by pharmaceutical companies involved in NASH clinical trials and how the K18 assays can result in both time and cost savings, and show efficacy of NASH drug treatment.

Read the post here!